Analysis of sequence configurations of the ISDR, PKR-Binding domain, and V3 region as predictors of response to induction interferon-α and ribavirin therapy in chronic hepatitis C infection

Digestive Diseases and Sciences

Volumn 47, Issue 6, 2002, Pages 1195-1205

  Murphy, Melissa D ^a,b   Rosen, Hugo R ^a,b   Marousek, Gail I ^a,b   Chou, Sunwen ^a,b  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Interferon sensitivity determining region (ISDR); Phosphorylation homology domain; PKR binding domain; PKR eIF 2 ; V3 region

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; PROTEIN KINASE; PROTEIN KINASE R; RIBAVIRIN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CODON; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RESPONSIVE ELEMENT; DNA STRUCTURE; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; GENE AMPLIFICATION; GENETIC VARIABILITY; HEPATITIS C; HUMAN; MALE; NATURAL SELECTION; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; SERUM; TREATMENT OUTCOME; VIRUS GENOME;

ADULT; AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; CODON; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; EIF-2 KINASE; EUKARYOTIC INITIATION FACTOR-2; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C ANTIGENS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; PHOSPHORYLATION; RIBAVIRIN; RNA, VIRAL; SEQUENCE HOMOLOGY, AMINO ACID; TREATMENT OUTCOME; VIRAL ENVELOPE PROTEINS;

EID: 0036277038     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1015349924116     Document Type: Article

References (34)

1. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994
2. Centers for Disease Control and Prevention: Recommendations for prevention and control of hepatitis C virus infection and HCV-related chronic disease
3. Interferon alfa- 2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
4. Randomised trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa- 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
5. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b
6. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa
7. Mutations in the NS 5A gene of hepatitis C virus in North American patients infected with HCV genotype 1a or 1b
8. Mutations of hepatitis C virus 1b NS5A 2209-2248 amino acid sequence do not predict the response to recombinant interferon-alfa therapy in French patients
9. Sequence analysis of the NS 5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity
10. The "interferon sensitivity determining region" of hepatitis C virus is a stable sequence element
11. Variation in the hepatitis C virus NS 5a region in relation to hypervariable region 1 heterogeneity during interferon treatment
12. Long-term response to interferon alpha is unrelated to "interferon sensitivity determining region" variability in patients with chronic hepatitis C virus- 1b infection
13. Mutations in the NS5A region do not predict interferon-responsiveness in American patients infected with genotype 1b hepatitis C virus
14. Response to retreatment with interferon-alpha plus ribavirin in chronic hepatitis C patients is independent of the NS 5A gene nucleotide sequence
15. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection
16. Mutations in the NS 5A gene predict response to interferon therapy in Japanese patients with chronic hepatitis C and cirrhosis
17. Number and position of mutations in the interferon sensitivity-determining region of the gene for non-structural protein 5A correlate with IFN efficacy in hepatitis C virus genotype 1b infection
18. The prognostic relevance of the nonstructural 5A gene interferon sensitivity determining region is different in infections with genotype 1b and 3a isolates of hepatitis C virus
19. Improved correlation between multiple mutations within the NS 5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy
20. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein
21. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: Molecular mechanisms of kinase regulation
22. Inhibition of the interferon-inducible protein kinase PKR by HCV E 2 protein
23. Management of hepatitis C
24. Interferon plus ribavirin for chronic hepatitis C
25. Efficacy, and changes of the nonstructural 5A gene by prolonged interferon therapy for patients with hepatitis C virus genotype 1b and a high level of serum HCV RNA
26. The epidemic behavior of the Hepatitis C virus
27. Genomic structure of the human prototype strain H of hepatitis C virus: Comparison with American and Japanese isolates
28. Association of amino acid sequence in the PKR-eIf 2 phosphorylation homology domain and response to interferon
29. Mutations in the protein kinase-binding domain of the NS 5A protein in patients infected with hepatitis C virus type 1a are associated with treatment response
30. Prospective characterization of full-length hepatitis C virus NS 5A quasispecies during induction and combination antiviral therapy
31. Expression of hepatitis C virus proteins interferes with the antiviral action of interferon independently of PKR-mediated control of protein synthesis
32. Hepatitis C virus NS5A protein inhibits interferon antiviral activity, but the effects do not correlate with clinical response
33. Hepatitis C virus, the E2 envelope protein, and α-interferon resistance
34. The amino acid sequence of the PKR-eIF2α phosphorylation homology domain of hepatitis C virus envelope 2 protein and response to interferon